MD970313A - Criptoficine noi obtinute prin sinteza - Google Patents

Criptoficine noi obtinute prin sinteza

Info

Publication number
MD970313A
MD970313A MD97-0313A MD970313A MD970313A MD 970313 A MD970313 A MD 970313A MD 970313 A MD970313 A MD 970313A MD 970313 A MD970313 A MD 970313A
Authority
MD
Moldova
Prior art keywords
cryptophycines
synthesis
prepared
new
chform
Prior art date
Application number
MD97-0313A
Other languages
English (en)
Other versions
MD2196B2 (ro
Inventor
Richard E Moore
Marcus TIUS
Russel A Barrow
Jian Liang
Thomas H Corbett
Frederick A Valeri-Ote
Thomas K Hemscheidt
Original Assignee
Univ Hawaii
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/400,057 external-priority patent/US6013626A/en
Priority claimed from US08/482,141 external-priority patent/US5952298A/en
Application filed by Univ Hawaii, Univ Wayne State filed Critical Univ Hawaii
Publication of MD970313A publication Critical patent/MD970313A/ro
Publication of MD2196B2 publication Critical patent/MD2196B2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MD97-0313A 1995-03-07 1996-03-07 Criptoficine, procedeu de obţinere, compoziţii farmaceutice pe baza acestora, metodă de inhibare a proliferării celulelor mamiferelor şi metodă de atenuare a stării patologice cauzate de hiperproliferarea celulelor mamiferelor MD2196B2 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/400,057 US6013626A (en) 1993-12-21 1995-03-07 Cryptophycins from synthesis
US08/482,141 US5952298A (en) 1993-12-21 1995-06-07 Cryptophycins
PCT/US1996/003246 WO1996040184A1 (en) 1995-03-07 1996-03-07 New cryptophycins from synthesis

Publications (2)

Publication Number Publication Date
MD970313A true MD970313A (ro) 1999-06-30
MD2196B2 MD2196B2 (ro) 2003-06-30

Family

ID=27016884

Family Applications (1)

Application Number Title Priority Date Filing Date
MD97-0313A MD2196B2 (ro) 1995-03-07 1996-03-07 Criptoficine, procedeu de obţinere, compoziţii farmaceutice pe baza acestora, metodă de inhibare a proliferării celulelor mamiferelor şi metodă de atenuare a stării patologice cauzate de hiperproliferarea celulelor mamiferelor

Country Status (23)

Country Link
EP (1) EP0830136B1 (ro)
JP (1) JP4181632B2 (ro)
CN (1) CN1165337C (ro)
AP (1) AP737A (ro)
AT (1) ATE279935T1 (ro)
AU (1) AU723652B2 (ro)
BG (1) BG63289B1 (ro)
CZ (1) CZ278197A3 (ro)
DE (1) DE69633667T2 (ro)
ES (1) ES2230561T3 (ro)
FI (1) FI973591A0 (ro)
GE (1) GEP20002206B (ro)
HK (1) HK1009747A1 (ro)
HU (1) HU225041B1 (ro)
MD (1) MD2196B2 (ro)
NO (1) NO326685B1 (ro)
NZ (1) NZ305571A (ro)
OA (1) OA10614A (ro)
PL (1) PL185949B1 (ro)
RO (1) RO118931B1 (ro)
SK (1) SK119997A3 (ro)
TJ (1) TJ347B (ro)
WO (1) WO1996040184A1 (ro)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000501067A (ja) * 1995-08-30 2000-02-02 イーライ・リリー・アンド・カンパニー 医薬化合物
US6680311B1 (en) 1996-08-30 2004-01-20 Eli Lilly And Company Cryptophycin compounds
JP2001500484A (ja) * 1996-08-30 2001-01-16 イーライ・リリー・アンド・カンパニー 医薬化合物の製造法
IL128610A (en) * 1996-08-30 2004-07-25 Lilly Co Eli Cryptophycin compound and its use as a medicament for treating neoplasm
EP0956295A1 (en) * 1996-09-06 1999-11-17 Eli Lilly And Company Process to prepare pharmaceutical compounds
KR20010029475A (ko) * 1996-09-06 2001-04-06 피터 지. 스트링거 약제학적 화합물의 제조 방법
JP2001502298A (ja) * 1996-09-06 2001-02-20 イーライ・リリー・アンド・カンパニー 方法および新規中間体
NZ336918A (en) * 1997-02-26 2001-11-30 Lilly Co Eli Selective epoxidation process for preparing pharmaceutical compounds comprising Cryptophycin 52
AU6338698A (en) * 1997-02-26 1998-09-18 Eli Lilly And Company Tripeptide and tetrapeptide pharmaceutical compounds
EP0870501A1 (en) * 1997-04-11 1998-10-14 Eli Lilly And Company Use of specific cryptophycin derivatives for the manufacture of a medicament in the treatment of fungal infections
EP0870506A1 (en) * 1997-04-11 1998-10-14 Eli Lilly And Company Compositions comprising a cryptophycin compound in combination with a synchronizing or activating agent for treating cancer
EP0870510A3 (en) * 1997-04-11 1999-09-15 Eli Lilly And Company Synergistic combination comprising cryptophycin derivatives and microtubule synergizing agents
US6103913A (en) * 1998-10-16 2000-08-15 Eli Lilly And Company Process for preparing enollactone derivatives
US6376230B1 (en) 1998-10-16 2002-04-23 Eli Lilly And Company Stereoselective process for producing intermediates of cryptophycins
AU1123200A (en) * 1998-10-16 2000-05-08 Eli Lilly And Company Stereoselective process for producing antineoplastic agents
WO2000034252A2 (en) * 1998-12-07 2000-06-15 Eli Lilly And Company Process for the preparation of cryptophycin derivatives
US6372936B1 (en) * 1999-06-09 2002-04-16 Eli Lilly And Company Optical resolution of aminoisobobutyric acid
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
US11530204B2 (en) * 2019-09-30 2022-12-20 The Regents Of The University Of Michigan Biocatalytic synthesis of cryptophycin anticancer agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946835A (en) * 1988-07-15 1990-08-07 Merck & Co., Inc. Antifungal fermentation product and method
US4868208A (en) * 1988-07-15 1989-09-19 Merck & Co., Inc. Antifungal agent and method
US4845086A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent
US4845085A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent
WO1995017093A1 (en) * 1993-12-21 1995-06-29 University Of Hawaii New cryptophycins

Also Published As

Publication number Publication date
ES2230561T3 (es) 2005-05-01
NO974105L (no) 1997-11-05
HK1009747A1 (en) 1999-06-11
EP0830136B1 (en) 2004-10-20
JP4181632B2 (ja) 2008-11-19
CN1165337C (zh) 2004-09-08
TJ347B (en) 2002-10-06
PL322507A1 (en) 1998-02-02
NO326685B1 (no) 2009-01-26
MD2196B2 (ro) 2003-06-30
JPH11510476A (ja) 1999-09-14
BG101875A (en) 1998-10-30
OA10614A (en) 2001-03-15
ATE279935T1 (de) 2004-11-15
WO1996040184A1 (en) 1996-12-19
CN1183726A (zh) 1998-06-03
HUP9801880A2 (hu) 1998-11-30
BG63289B1 (bg) 2001-09-28
FI973591A0 (fi) 1997-09-03
AU5360396A (en) 1996-12-30
EP0830136A1 (en) 1998-03-25
AP737A (en) 1999-03-15
GEP20002206B (en) 2000-08-25
DE69633667D1 (en) 2004-11-25
HU225041B1 (en) 2006-05-29
RO118931B1 (ro) 2004-01-30
CZ278197A3 (cs) 1998-12-16
DE69633667T2 (de) 2006-03-02
HUP9801880A3 (en) 1999-08-30
PL185949B1 (pl) 2003-09-30
EP0830136A4 (en) 2001-01-24
AP9701069A0 (en) 1997-10-30
NZ305571A (en) 1999-02-25
AU723652B2 (en) 2000-08-31
NO974105D0 (no) 1997-09-05
SK119997A3 (en) 1998-12-02

Similar Documents

Publication Publication Date Title
MD970313A (ro) Criptoficine noi obtinute prin sinteza
RU94046411A (ru) Производные витамина д, способ их получения, фармацевтическая композиция на их основе и способ ее получения, способ лечения
PL366198A1 (en) Novel compounds
MD1233B1 (ro) Derivati de eritromicina, procedeu de preparare a lor si compozitie farmaceu-tica pe baza acestora
AP9701041A0 (en) Pyridylpyrrole compounds.
HK1048990A1 (en) Novel compounds.
IL111077A (en) Pyridine derivatives processes for the preparation thereof and pharmaceutical compositions containing them
AU5799294A (en) Isoxazole-4-carboxamides and hydroxy-alkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
RU94036004A (ru) Промежуточные соединения для получения ароматических аминоспиртовых производных
MX9700885A (es) Nuevas heteroariloxazolidinonas.
HUT54119A (en) Process for producing antiinflammatory aminophenol derivatives
GB0013737D0 (en) Novel compounds
ZA9710796B (en) Oxyiminopregnanecarbolactones.
MY115211A (en) Novel amino acid derivatives, their preparation and use
MY120683A (en) New phenylamidine derivatives, processes for their preparation and their use as pharmaceuticals.
TR199700999T1 (xx) Askomisinler.
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
PL336640A1 (en) Substituted 3,3-diamino-2- propenonitriles, their production and application
NZ331683A (en) New indole and indazole compounds, a process for their preparation and pharmaceutical compositions containing them
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
HU9602413D0 (en) Novel tetrasubstituted imidazole derivatives, method for preparing same, resulting novel intermediates, use thereof as drugs, and pharmaceutical compositions containing same
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
MY114282A (en) Anthracycline derivatives
TR200101083T2 (tr) (7alfa,17alfa)-17-hidroksi- 7-metil-19-nor-17-pregn-5 (10)-en-20-in-3-on içeren yüksek saflıkta bileşim.
BG103260A (en) The application of 1-hydroxy-2-pyridons for the treatment of seborrheic dermatitis

Legal Events

Date Code Title Description
PD99 Pending application